Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1871-1879

  Motomura, Kazuya ^a   Natsume, Atsushi ^a   Watanabe, Reiko ^b   Ito, Ichiro ^b   Kato, Yukinari ^c   Momota, Hiroyuki ^a   Nishikawa, Ryo ^d   Mishima, Kazuhiko ^d   Nakasu, Yoko ^b   Abe, Tatsuya ^e   Namba, Hiroki ^f   Nakazato, Yoichi ^g   Tashiro, Hiroshi ^b   Takeuchi, Ichiro ^h   Mori, Tsutomu ⁱ   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CANCER CENTER   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^e OITA UNIVERSITY   (Japan)

^f HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g GUNMA UNIVERSITY   (Japan)

^h NAGOYA INSTITUTE OF TECHNOLOGY   (Japan)

ⁱ FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; HERMES ANTIGEN; NESTIN; PODOPLANIN; PROTEIN P16; PROTEIN P53; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; ASTROCYTE; BASE PAIRING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLUSTER ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMICS; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEOMICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PROTEOMICS; TRANSCRIPTOME; YOUNG ADULT;

EID: 84867231671     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02377.x     Document Type: Article

References (43)

1. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
2. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
3. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17: 510-22.
4. Kim TM, Huang W, Park R, Park PJ, Johnson MD. A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs. Cancer Res 2011; 71: 3387-99.
5. Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
6. Northcott PA, Korshunov A, Witt H et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011; 29: 1408-14.
7. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009; 390: 547-51.
8. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
9. Kleihues P, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: WHO Press, 2000.
10. Motomura K, Natsume A, Kishida Y et al. Benefits of interferon-beta and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: a multicenter study. Cancer 2011; 117: 1721-30.
11. Watanabe R, Nakasu Y, Tashiro H et al. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma. Brain Tumor Pathol 2011; 28: 127-35.
12. Franco-Hernandez C, Martinez-Glez V, Alonso ME et al. Gene dosage and mutational analyses of EGFR in oligodendrogliomas. Int J Oncol 2007; 30: 209-15.
13. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 2006; 8: 433-43.
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
15. Martinez-Glez V, Franco-Hernandez C, Lomas J et al. Multiplex ligation-dependent probe amplification (MLPA) screening in meningioma. Cancer Genet Cytogenet 2007; 173: 170-2.
16. Natsume A, Wakabayashi T, Tsujimura K et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008; 122: 2542-53.
17. Oi S, Natsume A, Ito M et al. Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2′-deoxycytidine in glioma cells. J Neurooncol 2009; 92: 15-22.
18. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15: 6002-7.
19. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992; 52: 674-9.
20. Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1, 010 diffuse gliomas. Acta Neuropathol 2009; 118: 469-74.
21. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 2003; 52: 91-118.
22. Rousseeuw PJ. Silhouettes - A graphical aid to the interpretation and validation of cluster-analysis. J Comput Appl Math 1987; 20: 53-65.
23. Team RDC. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2008.
24. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
25. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
26. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
27. Brennan C, Momota H, Hambardzumyan D et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 2009; 4: e7752.
28. Gravendeel LA, Kouwenhoven MC, Gevaert O et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res 2009; 69: 9065-72.
29. Nicolay DJ, Doucette JR, Nazarali AJ. Transcriptional control of oligodendrogenesis. Glia 2007; 55: 1287-99.
30. Hu BY, Du ZW, Li XJ, Ayala M, Zhang SC. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects. Development 2009; 136: 1443-52.
31. Levine JM, Reynolds R, Fawcett JW. The oligodendrocyte precursor cell in health and disease. Trends Neurosci 2001; 24: 39-47.
32. Nishiyama A, Lin XH, Giese N, Heldin CH, Stallcup WB. Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J Neurosci Res 1996; 43: 299-314.
33. Rao RC, Boyd J, Padmanabhan R, Chenoweth JG, McKay RD. Efficient serum-free derivation of oligodendrocyte precursors from neural stem cell-enriched cultures. Stem Cells 2009; 27: 116-25.
34. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005; 26: 195-200.
35. Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T. Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004; 23: 8552-6.
36. Kato Y, Kaneko MK, Kuno A et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006; 349: 1301-7.
37. Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol 2006; 111: 483-8.
38. Hantusch B, Kalt R, Krieger S, Puri C, Kerjaschki D. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol 2007; 8: 20.
39. Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol 2009; 129: 1321-4.
40. Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010; 70: 2455-64.
41. Martin-Villar E, Fernandez-Munoz B, Parsons M et al. Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell 2010; 21: 4387-99.
42. Wakabayashi T, Kayama T, Nishikawa R et al. A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol 2008; 38: 715-8.
43. Wakabayashi T, Kayama T, Nishikawa R et al. A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study): the final report. J Neurooncol 2011; 104: 573-7.